Indeed, ADAM12 has been previously implicated in HB-EGF shedding44, 45, 47, and ADAM12 represents a compelling drug target through clinical association with diseases including hypertension, asthma, liver fibrosis, obesity, adverse pregnancy outcome, along with multiple cancers48. Here, HBEGF is linked to Obesity.